The role of polyamines in human cancer: prospects for drug combination therapies.

Date

2004-12

Contributor

Advisor

Department

Instructor

Depositor

Speaker

Researcher

Consultant

Interviewer

Narrator

Transcriber

Annotator

Journal Title

Journal ISSN

Volume Title

Publisher

Volume

63

Number/Issue

12

Starting Page

Ending Page

Alternative Title

Abstract

Ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) are two key enzymes in polyamine (PA) biosynthesis and their inhibition leads to PA pool depletion and cell growth arrest. DFMO and SAM486A are specific inhibitors of ODC and AdoMetDC, respectively, and are the only two PA inhibitors, which have been clinically evaluated in Phase II and III cancer trials. However, drug combination therapies expected to potentiate the effects of these drugs have yet to be systematically pursued. Human cancer trials (e.g. for the treatment of neuroblastoma patients) using a DFMO/SAM486A cocktail, possibly combined with current cytotoxic drugs and concomitant with a PA-deficient diet, are warranted.

Description

Keywords

Citation

Extent

Format

Geographic Location

Time Period

Related To

Related To (URI)

Table of Contents

Rights

Rights Holder

Local Contexts

Email libraryada-l@lists.hawaii.edu if you need this content in ADA-compliant format.